Table 1 Patients’ characteristics at baseline
| Â | Number (%) of patients | |||
|---|---|---|---|---|
| Â | Ganetespib | Ganetespib | Ganetespib | All |
7-114Â mg/m2 | 150-216Â mg/m2 | 259Â mg/m2 | patients | |
n = 25 (%) | n = 22 (%) | n = 6 (%) | n = 53 (%) | |
Age (years) | ||||
 Median (range) | 61 (39, 87) | 62 (37, 80) | 61 (47, 81) | 61 (37, 87) |
Sex, n (%) | ||||
 Female | 14 (56) | 7 (31.8) | 3 (50) | 24 (45.3) |
 Male | 11 (44) | 15 (68.2) | 3 (50) | 29 (54.7) |
Race, n (%) | ||||
 White | 24 (96) | 19 (86.4) | 6 (100) | 49 (92.5) |
 Black | 0 | 2 (9.1) | 0 | 2 (3.8) |
 Other | 1 (4) | 1 (4.5) | 0 | 2 (3.8) |
ECOG PS, n (%) | ||||
 0 | 10 (40) | 5 (22.7) | 2 (33.3) | 17 (32.1) |
 1 | 13 (52) | 17 (77.3) | 4 (66.7) | 34 (64.2) |
 2 | 2 (8) | 0 | 0 | 2 (3.8) |
Primary tumor site, n (%) | ||||
 NSCLC | 5 (20) | 3 (13.6) | 2 (33.3) | 10 (18.9) |
 colorectal | 2 (8) | 6 (27.3) | 0 | 8 (15.1) |
 Prostate | 3 (12) | 0 | 0 | 3 (5.7) |
 Esophageal | 1 (4) | 2 (9.1) | 0 | 3 (5.7) |
 SCLC | 1 (4) | 1 (4.5) | 0 | 2 (3.8) |
 Pancreas | 1 (4) | 1 (4.5) | 0 | 2 (3.8) |
 Ovarian | 2 (8) | 0 | 0 | 2 (3.8) |
 Others | 10 (40) | 9 (40.9) | 4 (66.7) | 23 (43.3) |
Tumor stage at study entry, n (%) | ||||
 III | 2 (8) | 0 | 0 | 2 (3.8) |
 IV | 23 (92) | 22 (100) | 6 (100) | 51 (96.2) |
Number of prior systemic therapies, n (%) | ||||
 0 | 1 (4) | 1 (4.5) | 0 | 2 (3.8) |
 1 | 0 | 2 (9.1) | 1 (16.7) | 3 (5.7) |
 2-3 | 7 (28) | 6 (27.3) | 3 (50) | 16 (30.2) |
 ≥ 3 | 17 (68) | 13 (59.1) | 2 (33.3) | 32 (60.4) |